{"prompt": "['15. REFERENCES', '1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin', '2011;61:69-90.', '2. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J et al. Capecitabine/cisplatin versus 5-', 'fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III', 'noninferiority trial. Ann Oncol 2009;20:666-73.', '3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F et al; Upper Gastrointestinal Clinical', 'Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin', 'for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.', '4. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R et al. Phase III trial in', 'metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin. J', 'Clin Oncol 2008;26:1435-42.', '5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al. Trastuzumab in combination', 'with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-', 'oesophageal junction cancer (ToGA) : a phase 3, openlabel, randomised controlled trial. Lancet 2010;376:687-', '97.', '6. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C et al; V325 Study Group.', 'Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line', 'therapy for advanced gastric cancer. J Clin Oncol 2006;24:4991-7.', '7. Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F et al. Docetaxel plus oxaliplatin with', 'or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. Ann Oncol 2015;26:149-', '56.', '8. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J et al. Docetaxel versus active', 'symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an openlabel, phase 3', 'randomised controlled trial. Lancet Oncol 2014;15:78-86.', '9. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T et al. Randomized, open-label, phase III study', 'comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal', 'metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007', 'trial. J Clin Oncol 2013;31:4438-44.', '10. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K et al. Survival advantage for', 'irinotecan versus best supportive care as second-line chemotherapy in gastric cancer- A randomised phase III', 'study of the Arbeitsgemeinschaft internistische onkologie (AIO). Eur J Cancer 2011;47:2306-14.', '11. Fuchs CS, Tomasek J, Yang CJ, Dumitru F, Passalacqua R, Goswami C et al. Ramucirumab monotherapy', 'for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an', 'international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-9.', '12. Wilke H, K Muro, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al. Ramucirumab plus paclitaxel versus', 'placebo plus paclitaxel I patients with previously treated advanced gastric or gastro-oesophageal junction', 'adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial. Lancet Oncol 2014;15:1224-35.', '13. Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andr\u00e9 T et al. Prospective, randomized, multicenter,', 'phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in', 'advanced gastric adenocarcinoma: a French intergroup (F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive,', 'F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer and Groupe Coop\u00e9rateur Multidisciplinaire en', 'Oncologie) study. J Clin Oncol 2014;32:3520-6.', '14. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S et al. Pembrolizumab for patients with', 'PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet', 'Oncol 2016;17:717-26.', '15. Fuchs CS, Doi T, Woo-Jun Jang R, Muro K, Satoh T, Machado M et al. KEYNOTE-059 cohort 1: Efficacy', 'and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.', 'J Clin Oncol 2017;35 (suppl; abstr 4003).', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 48 de 123']['16. Yamada Y, Nishina T, Iwasa S, Shitara K, Muro K, Esaki T et al. A phase I dose expansion trial of', 'avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer. J Clin', 'Oncol 2015;33 (suppl; abstr 4047).', '17. Janjigian YY, Ott PA, Calvo E, Kim JW, Ascierto PA, Sharma P et al. Nivolumab ipilimumab in pts with', 'advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal', 'junction (GEJ) cancer: CheckMate 032 study. J Clin Oncol 2017;35 (suppl; abstr 4014).', '18. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J et al. Safety and Efficacy of Durvalumab', '(MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With', 'Advanced Urothelial Bladder Cancer. J Clin Oncol 2016;34:3119-25.', '19. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for', 'optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010;16:3100-4.', '20. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X et al. Preliminary data from a multi-', 'arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol 2014;32 (suppl; abstr 3002).', '21. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour', 'activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet', 'Oncol. 2016;17(3):299-308.', '22. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S et al; RECIST working group.', 'iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol', '2017;18:e143-e152.', '23. Samalin E, Afchain P, Th\u00e9zenas S, Abbas F, Romano O, Guimbaud R et al. Efficacy of irinotecan in', 'combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas', '(MGA) treatment. Clin Res Hepatol Gastroenterol 011;35:48-54.', '24. Maugeri-Sacc\u00e0 M, Pizzuti L, Sergi D, Barba M, Belli F, Fattoruso S et al. FOLFIRI as a second-line therapy', 'in patients with docetaxel-pretreated gastric cancer: a historical cohort. J Exp Clin Cancer Res 2013;32:67.', '25. Kim SH, Lee GW, Go SI, Cho SH, Kim HJ, Kim HG et al. A phase II study of irinotecan, continuous 5- -', 'fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic', 'gastric cancer previously treated with a fluoropyrimidine-based regimen. Am J Clin Oncol 2010;33:572-6.', \"26. A'Hern R. P., Sample size tables for exact single-stage phase II designs. Statistics in medicine 2001; 20:859\", '- 866', '27. Kaplan EL and Meier P. Nonparametric Estimation from Incomplete Observation. Journal of the American', 'Statistical Association 1958;53:457-481', '28. Schemper M and Smith TL. \"A Note on Quantifying Follow-up in Studies of Failure Time\" Control Clin', 'Trials 1996;17:343-6.', '16.ADMINISTRATIVE CONSIDERATIONS', 'TRIAL SPONSOR', 'The trial sponsor is the FFCD. The trial is registered under the EudraCT number 2018-002014-13.', 'REMINDER CONCERNING APPLICABLE REGULATIONS', 'This trial will be conducted in accordance with current French law, with the ethical principles of the Helsinki', 'Declaration of 1964 and its subsequent revisions, with Good Clinical Practice of the International Conference on', 'Harmonization (ICH-E6, 17/07/96), with European directive 2001/20/EC on the conduct of clinical trials, with', 'the Huriet Act as amended (20/12/88) on the protection of persons participating in biomedical research, and', 'with the provisions laid down by the CNIL, the French data protection agency (Act no. 94-548 of 01/07/94', 'completing Act no. 78-17 of 06/01/78).', 'PUBLIC LIABILITY INSURANCE', 'An insurance policy was taken out by the sponsor on 29/11/2018 under the number 137.681, in accordance with', 'article L 1121-10 - of the French Public Health Code (Appendix 13).', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 49 de 123']\n\n###\n\n", "completion": "END"}